Koomans H A, Boer W H, Dorhout Mees E J
Department of Nephrology and Hypertension, University Hospital Utrecht, The Netherlands.
Kidney Int. 1989 Jul;36(1):2-12. doi: 10.1038/ki.1989.153.
Estimations of proximal tubule sodium reabsorption with the FELi method come closer to direct measurements than any other indirect method. There is little doubt that most lithium reabsorption takes place in the proximal tubules, very likely in proportion to the reabsorption of sodium and water. It is also likely that changes in proximal tubule sodium reabsorption due to changes in volume status are paralleled by changes in proximal tubule lithium reabsorption, at least in the superficial nephrons. Nonetheless, changes in FELi probably do not purely reflect changes in proximal reabsorption, since lithium is also handled beyond the proximal tubules. Acknowledged problems are lithium reabsorption in Henle's loop and in the late distal and collecting tubules. The latter occurs in the rat and the dog, but not or much less in men. Sodium restriction enhances this lithium transport considerably. It is as yet uncertain whether other conditions, such as increased vasopressin activity or lowering of renal perfusion pressure, also influence this transport. Amiloride appears to prevent this reabsorption of lithium. Therefore, this drug can be used in lithium clearance studies whenever unwanted "distal" lithium reabsorption is expected. Lithium reabsorption in Henle's loop forms a greater problem as it cannot be prevented by any drug without influencing proximal tubule reabsorption. It is estimated that about 7% of the filtered lithium (one-tenth of total lithium reabsorption) is normally taken up here, preferentially in deep nephrons. In view of studies with furosemide, this reabsorption probably varies with sodium intake, but the proportion of this variation to that of proximal tubule lithium reabsorption is obscure. This remains an uncertain factor in any circumstance where the lithium clearance method is used. In some conditions the change in FELi may be so large relative to the expected changes in proximal reabsorption, that use of FELi as marker of end-proximal solute delivery seems unjustified. Disproportionately large suppression is likely during mineralo-corticoid-induced volume expansion, and stimulation during prostaglandin synthesis inhibition and vasopressin. Based on observations in these conditions the potential range of lithium reabsorption in the loop of Henle would be 0 to 15% of filtered load. In this review attention was paid mainly to the validity of lithium clearance as a pure "proximal marker". Many of our interpretations suffer from incomplete certainty with respect to the renal effects of tested maneuvers, a problem which is acknowledged.(ABSTRACT TRUNCATED AT 400 WORDS)
用FELi法估算近端小管钠重吸收比其他任何间接方法都更接近直接测量值。毫无疑问,大多数锂的重吸收发生在近端小管,很可能与钠和水的重吸收成比例。由于容量状态变化导致的近端小管钠重吸收变化,很可能至少在浅表肾单位中与近端小管锂重吸收变化平行。然而,FELi的变化可能并不纯粹反映近端重吸收的变化,因为锂在近端小管之外也会被处理。公认的问题是锂在髓袢以及远曲小管和集合管后期的重吸收。后者在大鼠和狗中会发生,但在人类中不会或很少发生。钠限制会显著增强这种锂转运。目前尚不确定其他情况,如血管升压素活性增加或肾灌注压降低,是否也会影响这种转运。氨氯地平似乎可以阻止锂的这种重吸收。因此,每当预期会出现不必要的“远端”锂重吸收时,这种药物可用于锂清除率研究。髓袢中锂的重吸收是一个更大的问题,因为没有任何药物可以在不影响近端小管重吸收的情况下阻止它。据估计,正常情况下约7%的滤过锂(占总锂重吸收的十分之一)在此处被重吸收,优先在深部肾单位。鉴于使用速尿的研究,这种重吸收可能随钠摄入量而变化,但这种变化与近端小管锂重吸收变化的比例尚不清楚。在任何使用锂清除率方法的情况下,这仍然是一个不确定因素。在某些情况下,相对于预期的近端重吸收变化,FELi的变化可能非常大,以至于将FELi用作近端溶质输送终点的标志物似乎不合理。在盐皮质激素诱导的容量扩张期间可能会出现不成比例的大幅抑制,而在前列腺素合成抑制和血管升压素作用期间则会出现刺激。基于在这些情况下的观察,髓袢中锂重吸收的潜在范围为滤过负荷的0%至15%。在本综述中,主要关注锂清除率作为纯“近端标志物”的有效性。我们的许多解释在受试操作对肾脏的影响方面存在不完全确定性的问题,这是一个公认的问题。(摘要截断于400字)